Testing an antibody treatment for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had chronic hepatitis B for more than 6 months.
- You have been taking a stable oral antiviral medication (like tenofovir or entecavir) for over a year.
- Your hepatitis B virus DNA is undetectable and your liver enzymes are normal.
- You do not have advanced liver scarring (cirrhosis), liver cancer, or other serious liver diseases.
- You are not pregnant, breastfeeding, and agree to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug called AHB-171 in people with chronic hepatitis B infection. The trial aims to see how safe the drug is and how well it works to help control the virus.
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
This trial tests an investigational injection called TQA3038 for people with chronic hepatitis B who still have active virus (HBeAg positive). It may help reduce the virus and improve liver health. The study is for adults 18 to 65 who are already on oral antiviral pills or have never been treated.
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
This Phase 1 trial tests HepB mAb19, an antibody medicine, in adults with chronic hepatitis B. The goal is to see how it works and how safe it is in people whose hepatitis B is controlled on current antiviral treatment.
Hear when a new Hepatitis B, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.